TECENTRIQ (atezolizumab) received FDA approval for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. The agent is sponsored by Genentech, a member of the Roche Group....
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
